Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.

The difference in responder proportion (0.10), however, did not reach statistical significance (80% CI −0.07 to 0.25).

also in 111,027 other papers

While there was a numerical trend toward clinical improvement in active RA symptoms with spebrutinib treatment, the effect was not statistically significant. 11 Acalabrutinib was studied in a phase IIa trial with 31 RA patients on background MTX, assessed with a composite index of active rheumatoid arthritis, known as disease activity score 28-C-reactive protein (DAS28-CRP).

also in 1,012 other papers